Does a GLP-1 Receptor Agonist Change Glucose Tolerance in Antipsychotic-treated Patients?

NCT01845259 · Unknown status

Last updated 2026-05-28

This clinical trial is testing whether a GLP-1 receptor agonist can improve glucose tolerance in people taking antipsychotic medications.

Status Unknown status The sponsor has not confirmed the status recently.

Phase Phase 2 Tests whether it works and watches safety in a moderate group.

Type Interventional (clinical trial)

Design Randomized, quadruple-blind treatment study

Participants 103 people

Who can join Ages 18–65 · all sexes

Timeline Started 2013-04 · est. completion 2017-03

Where 1 site · Denmark

What this study is testing ClinicalTrials.gov NCT01845259 ↗

Description as written by the study sponsor.

Metabolic disturbances, obesity and life-shortening cardiovascular morbidity are major clinical problems among antipsychotic-treated patients. Especially two of the most efficacious antipsychotics, clozapine and olanzapine, cause weight gain and metabolic disturbances and can rarely be replaced by other drugs due to the effectiveness of the compounds. Glucagon-like peptide 1 (GLP-1) has improved glycemic control among patients with type 2 diabetes. The study will investigate whether the beneficial effects of GLP-1 analogues on glycemic control in type 2 diabetic patients, can be extended to a population of non-diabetic, dysglycemic psychiatric patients, receiving antipsychotic medical treatment.

Treatments tested

Liraglutide also known as Victoza, GLP-1 agonist Drug

Once a day 1,8 mg subcutaneous injection for 16 weeks
Liraglutide Placebo also known as Placebo Drug

Once a day 1,8 mg subcutaneous injection for 16 weeks

Main thing measured	Glucose tolerance
Sponsor	Psychiatric Centre Rigshospitalet
Conditions studied	Impaired Glucose Tolerance Associated With Drugs
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT01845259 ↗